These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38303281)

  • 21. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
    Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.
    Sasaki K; Tsuruda Y; Shimonosono M; Noda M; Uchikado Y; Arigami T; Matsushita D; Mori S; Nakajo A; Kurahara H; Ohtsuka T
    Anticancer Res; 2022 Aug; 42(8):3905-3911. PubMed ID: 35896244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.
    Watanabe M; Nagai Y; Kinoshita K; Saito S; Kurashige J; Karashima R; Hirashima K; Sato N; Imamura Y; Hiyoshi Y; Baba Y; Iwagami S; Miyamoto Y; Iwatsuki M; Hayashi N; Baba H
    Digestion; 2011; 83(3):146-52. PubMed ID: 21266808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
    Ishikawa T; Yasuda T; Okayama T; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Konishi H; Naito Y; Teramukai S; Itoh Y
    Cancer Sci; 2019 Dec; 110(12):3754-3760. PubMed ID: 31646714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network.
    Tankel J; Ahmed N; Mueller C; Najmeh S; Spicer J; Mulder D; Cool-Lartigue J; Rousseau M; Frechette D; Sud S; Kavan P; Moghrabi A; Champagne M; Lemay F; Dalfen R; Sirhan S; Asselah J; Alcindor T; Ferri L
    Ann Surg Oncol; 2024 Apr; 31(4):2461-2469. PubMed ID: 38142255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current status of neoadjuvant chemotherapy for advanced esophageal cancer].
    Tanabe S; Shirakawa Y; Maeda N; Katsube R; Ohara T; Sakurama K; Noma K; Fujiwara T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1612-4. PubMed ID: 24393865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
    Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
    Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer.
    Maeda O; Furune S; Kanda M; Miyata K; Shimizu D; Sugita S; Nishida K; Ando M; Kodera Y; Ando Y
    Cancer Med; 2024 Jan; 13(2):e6974. PubMed ID: 38348961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A Case of Advanced Esophageal Cancer with pCR after Preoperative DCF Chemotherapy].
    Suzuki A; Nishimura T; Somura H; Setoguchi M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1947-1949. PubMed ID: 38303260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
    Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
    Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
    Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
    Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
    Katsumi C; Bamba T; Nakagawa S; Aizawa M; Matsuki A; Yabusaki H; Homma K
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):75-78. PubMed ID: 28174385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A Case of Esophageal Cancer Achieving a Pathological Complete Response after Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy].
    Motegi D; Ichikawa H; Kano Y; Hanyu T; Ishikawa T; Usui K; Sakai T; Hirose Y; Miura K; Nagahashi M; Shimada Y; Sakata J; Kobayashi T; Kameyama H; Wakai T
    Gan To Kagaku Ryoho; 2019 Dec; 46(13):2192-2194. PubMed ID: 32156875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.